General Information of Drug (ID: DMRYL9X)

Drug Name
AP-2243 Drug Info
Synonyms AP-2243; CHEMBL244416; BDBM50218528; 3-{4-[(benzylethylamino)methyl]phenyl}-6,7-dimethoxychromen-2-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
23643351
TTD Drug ID
DMRYL9X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Acetylcholinesterase (AChE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [2]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [3]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [4]
Galantamine DMEO794 Alzheimer disease 8A20 Approved [5]
Huperzine A DMMAWLU Alzheimer disease 8A20 Approved [6]
Neostigmine DM6T2J3 Myasthenia gravis 8C6Y Approved [7]
YM443 DMNZCI1 Functional dyspepsia DD90.3 Approved [8]
Ambenonium DMOP0BL Myasthenia gravis 8C6Y Approved [9]
Demecarium bromide DMAYEU1 Open-angle glaucoma 9C61 Approved [10]
Isoflurophate DMBSK7X Glaucoma/ocular hypertension 9C61 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Beta-secretase (BACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [12]
E-2609 DMTNUJ8 Alzheimer disease 8A20 Phase 3 [13]
verubecestat DM4CGH5 Alzheimer disease 8A20 Phase 3 [14]
Lanabecestat DMFJLB6 Alzheimer disease 8A20 Phase 3 [15]
AZD3293 DMJQHXD Alzheimer disease 8A20 Phase 2/3 [16]
JNJ-54861911 DMGPJ5U Alzheimer disease 8A20 Phase 2/3 [15]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [12]
LY2886721 DMV14LM Alzheimer disease 8A20 Phase 2 [17]
LY3202626 DM7IFNB Alzheimer disease 8A20 Phase 2 [15]
AZD-3839 DM72FOD Alzheimer disease 8A20 Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [1]
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [1]

References

1 Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6.
2 Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
4 Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
5 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
6 Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
7 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
10 The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
11 Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
12 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
13 Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
14 BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
17 Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
18 Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.